• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Focal Therapeutics touts BioZorb breast cancer implant data

Focal Therapeutics touts BioZorb breast cancer implant data

October 25, 2016 By Fink Densford

Focal TherapeuticsFocal Therapeutics today released data from 2 studies of its BioZorb device designed to provide radiographic markings of soft tissue sites.

The marker is made up of a bioabsorbable framework holding 6 titanium clips. The framework dissolves over a year in the body, the company said, while the clips stay in place so the surgical site can be recognizable during long-term monitoring.

The studies explored the use of the BioZorb device’s use during breast cancer procedures, according to the Aliso Viejo, Calif.-based company.

The BioZorb device can be placed during lumpectomy surgery to identify the 3 dimensional region where the tumor was removed. The company said the device is ‘particularly effective’ when sutured to the tumor bed for future indication of where the cancer was located.

Data from the 1st study was published in the World Journal of Surgery and reported that the device provided “clear visualization” of the surgical site where the tumor was removed and allowed for better communication between the surgeon and the radiation oncologist. The device also aided in post-treatment mammograms and other long-term follow-ups for cancer, according to the study.

“Through our experience with this marker, we’ve observed that its use results in less radiation dose to the patient compared to whole breast radiation, plus a better overall cosmetic outcome. We were also pleased to note in our research that there were no device-related complications in this group of patients, and that none of them had a recurrence of cancer,” study lead author Dr. Michael Cross of Fayetteville, Ark.’s Breast Treatment Associates said in prepared remarks.

Data from the 2nd study indicated that use of the BioZorb device can lower the amount of time normal breast and surrounding tissues are exposed to radiation treatment.

“The process of delivering radiation treatment is substantially streamlined by having the 3D marker in place. The marker tells us where the tumor was and helps us determine appropriate forms of treatment, whether with partial breast irradiation or standard whole breast irradiation and a boost dose at the end of the treatment process,” study author Dr. William Hall said in a press release.

Filed Under: Clinical Trials Tagged With: Focal Therapeutics

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy